Lanepitant HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598286

CAS#: 170508-05-1

Description: Lanepitant HCl is a potent non-peptide neurokinin-1 receptor antagonist, inhibits neurogenic dural inflammation.


Price and Availability

Size
Price

Size
Price

Size
Price

Lanepitant HCl is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 598286
Name: Lanepitant HCl
CAS#: 170508-05-1
Chemical Formula: C33H47Cl2N5O3
Exact Mass:
Molecular Weight: 632.67
Elemental Analysis: C, 62.65; H, 7.49; Cl, 11.21; N, 11.07; O, 7.59


Related CAS #: 167678-33-3 (HCl Trihydrate)  

Synonym: Lanepitant dihydrochloride; LY-303870 dihydrochloride; LY 303870 dihydrochloride; LY303870 dihydrochloride;

IUPAC/Chemical Name: (R)-N-(1-(1H-indol-3-yl)-3-(N-(2-methoxybenzyl)acetamido)propan-2-yl)-2-([1,4'-bipiperidin]-1'-yl)acetamide dihydrochloride

InChi Key: WURFRVBOVGQPHZ-QDSLRZTOSA-N

InChi Code: InChI=1S/C33H45N5O3.2ClH/c1-25(39)38(22-26-10-4-7-13-32(26)41-2)23-28(20-27-21-34-31-12-6-5-11-30(27)31)35-33(40)24-36-18-14-29(15-19-36)37-16-8-3-9-17-37;;/h4-7,10-13,21,28-29,34H,3,8-9,14-20,22-24H2,1-2H3,(H,35,40);2*1H/t28-;;/m1../s1

SMILES Code: O=C(N[C@H](CC1=CNC2=C1C=CC=C2)CN(C(C)=O)CC3=CC=CC=C3OC)CN4CCC(N5CCCCC5)CC4.[H]Cl.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Bignami F, Giacomini C, Lorusso A, Aramini A, Rama P, Ferrari G. NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6783-94. doi: 10.1167/iovs.14-14553. PubMed PMID: 25228541.

2: Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia. 1997 Nov;17(7):785-90. PubMed PMID: 9399010.

3: Goldstein DJ, Wang O, Todd LE, Gitter BD, DeBrota DJ, Iyengar S. Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin Pharmacol Ther. 2000 Apr;67(4):419-26. PubMed PMID: 10801252.

4: Goldstein DJ, Offen WW, Klein EG, Phebus LA, Hipskind P, Johnson KW, Ryan RE Jr. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia. 2001 Mar;21(2):102-6. PubMed PMID: 11422091.

5: Goldstein DJ, Wang O, Gitter BD, Iyengar S. Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol. 2001 Jan-Feb;24(1):16-22. PubMed PMID: 11290877.

6: Chaïr-Yousfi I, Laraba-Djebari F, Hammoudi-Triki D. Androctonus australis hector venom contributes to the interaction between neuropeptides and mast cells in pulmonary hyperresponsiveness. Int Immunopharmacol. 2015 Mar;25(1):19-29. doi: 10.1016/j.intimp.2015.01.008. Epub 2015 Jan 16. PubMed PMID: 25601496.

7: Wei T, Guo TZ, Li WW, Kingery WS, Clark JD. Acute versus chronic phase mechanisms in a rat model of CRPS. J Neuroinflammation. 2016 Jan 19;13:14. doi: 10.1186/s12974-015-0472-8. PubMed PMID: 26785976; PubMed Central PMCID: PMC4719337.

8: Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, Zu J, Zhang W, Shen X, Cui G, Hua F. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Exp Neurol. 2015 Sep;271:168-74. doi: 10.1016/j.expneurol.2015.05.007. Epub 2015 May 20. PubMed PMID: 26001615.

9: Shi X, Wang L, Clark JD, Kingery WS. Keratinocytes express cytokines and nerve growth factor in response to neuropeptide activation of the ERK1/2 and JNK MAPK transcription pathways. Regul Pept. 2013 Sep 10;186:92-103. doi: 10.1016/j.regpep.2013.08.001. Epub 2013 Aug 17. PubMed PMID: 23958840; PubMed Central PMCID: PMC3799830.

10: Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology. 2012 Apr;116(4):882-95. doi: 10.1097/ALN.0b013e31824bb303. PubMed PMID: 22343473; PubMed Central PMCID: PMC3311711.

11: Sahbaie P, Shi X, Li X, Liang D, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, David Clark J. Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice. J Pain. 2012 Oct;13(10):997-1007. doi: 10.1016/j.jpain.2012.07.009. PubMed PMID: 23031399; PubMed Central PMCID: PMC3491068.

12: Phebus LA, Johnson KW, Stengel PW, Lobb KL, Nixon JA, Hipskind PA. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci. 1997;60(18):1553-61. PubMed PMID: 9126877.

13: Gehlert DR, Schober DA, Hipskind PA, Gitter BD, Howbert JJ. [3H]LY303870, a novel nonpeptide radioligand for the NK-1 receptor. J Neurochem. 1996 Mar;66(3):1095-102. PubMed PMID: 8769871.

14: Sahbaie P, Shi X, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, Clark JD. Role of substance P signaling in enhanced nociceptive sensitization and local cytokine production after incision. Pain. 2009 Oct;145(3):341-9. doi: 10.1016/j.pain.2009.06.037. Epub 2009 Aug 5. PubMed PMID: 19660865; PubMed Central PMCID: PMC2746201.

15: Sendo T, Itoh Y, Goromaru T, Hirakawa T, Ishida M, Nakano H, Oishi R. Role of substance P in hypersensitivity reactions induced by paclitaxel, an anticancer agent. Peptides. 2004 Jul;25(7):1205-8. PubMed PMID: 15245881.

16: Campbell EA, Gentry CT, Patel S, Panesar MS, Walpole CS, Urban L. Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a model of neuropathic pain in the guinea-pig. Neuroscience. 1998 Dec;87(3):527-32. PubMed PMID: 9758219.

17: Li WW, Guo TZ, Liang D, Shi X, Wei T, Kingery WS, Clark JD. The NALP1 inflammasome controls cytokine production and nociception in a rat fracture model of complex regional pain syndrome. Pain. 2009 Dec 15;147(1-3):277-86. doi: 10.1016/j.pain.2009.09.032. Epub 2009 Oct 22. PubMed PMID: 19853379; PubMed Central PMCID: PMC5515229.

18: Sonea IM, Palmer MV, Akili D, Harp JA. Treatment with neurokinin-1 receptor antagonist reduces severity of inflammatory bowel disease induced by Cryptosporidium parvum. Clin Diagn Lab Immunol. 2002 Mar;9(2):333-40. PubMed PMID: 11874873; PubMed Central PMCID: PMC119952.

19: Kingery WS, Davies MF, Clark JD. A substance P receptor (NK1) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II. Pain. 2003 Jul;104(1-2):75-84. PubMed PMID: 12855316.

20: Deschamps K, Couture R. The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation. Br J Pharmacol. 2005 Jul;145(6):712-27. PubMed PMID: 15895109; PubMed Central PMCID: PMC1576198.